Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors during the central anxious process, conolidine modulates alternate molecular targets. A Science Developments research discovered that conolidine interacts Together with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://chelwoodv581wtr0.blogdiloz.com/profile